Thus, the utilization of p53‐dependent mechanisms in novel therapies might be effective for MMs carrying wild‐type TP53. One possible method to improve the efficacy of CPT‐11 or other CES2‐dependent prodrugs such as gemcitabine [25] could be the direct activation of p53 in cancer tissues to induce CES2 locally [16, 17, 18]. This evidence concerns the gene TP53 and cancer.